Parkinson Disease

Parkinson Disease (PD) 

Pathology 

The pathology of PD involves the gradual and selective loss of neurons in the brain, particularly in the substantia nigra, a region responsible for the production of dopamine—a neurotransmitter essential for controlling movement.

1. Lewy Bodies and α-Synuclein Aggregation:

   • A hallmark of PD pathology is the presence of Lewy bodies, abnormal protein inclusions primarily composed of misfolded α-synuclein protein. These aggregates are found in the neurons of PD patients and are associated with cell death and neurodegeneration.

   • The aggregation of α-synuclein disrupts normal cellular functions, including protein degradation, mitochondrial function, and synaptic transmission, leading to neuron dysfunction.

2. Mitochondrial Dysfunction:

   • Mitochondria in the neurons of PD patients show signs of dysfunction, leading to reduced energy production and increased oxidative stress. This can trigger cell death pathways, contributing to the progressive nature of the disease.

3. Neuroinflammation:

   • Chronic activation of microglia, the brain's resident immune cells, contributes to the inflammatory environment observed in PD. The release of pro-inflammatory cytokines can exacerbate neuronal injury and drive the disease progression.

Symptoms

PD presents with a variety of symptoms that can be classified into motor and non-motor categories:

1. Motor Symptoms:

   • Tremor: Typically a resting tremor, often starting in one hand.

   • Bradykinesia: Slowness of movement, affecting daily activities.

   • Muscle Rigidity: Stiffness in the limbs, leading to decreased range of motion.

   • Postural Instability: Impaired balance and coordination, leading to an increased risk of falls.

2. Non-Motor Symptoms:

   • Cognitive Impairment: Difficulty with attention, planning, and executive functions.

   • Mood Disorders: Depression, anxiety, and apathy are common in PD.

   • Autonomic Dysfunction: Problems with blood pressure regulation, constipation, and bladder control.

   • Sleep Disturbances: Insomnia, REM sleep behavior disorder, and excessive daytime sleepiness.

Outcome

 The outcome of PD varies significantly among patients and depends on the severity, rate of progression, and treatment:

1. Progression:

   • PD is a chronic and progressive disorder. While early symptoms are often mild, motor and non-motor symptoms gradually worsen over time.

   • Motor symptoms, such as bradykinesia and rigidity, typically become more severe, leading to significant impairment in daily activities.

2. Cognitive Decline:

   • As the disease advances, many patients experience cognitive decline, potentially developing Parkinson's disease dementia (PDD), which significantly impacts quality of life.

3. Quality of Life:

   • Progressive motor and non-motor symptoms contribute to disability, requiring increasing levels of care and support. The disease can lead to challenges in mobility, communication, and emotional well-being.

4. Mortality:

   • PD is not directly fatal, but complications such as falls, pneumonia, and general physical decline can increase mortality risk. With proper management and support, many individuals live with PD for decades.

Risk Factors